- Home
- PLUR vs CUE Comparison
PLUR vs CUE Comparison
Compare PLUR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | CUE |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Israel | United States |
| Employees | N/A | 41 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 27.8M |
| IPO Year | 2001 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PLUR | CUE |
|---|---|---|
| Price | $3.31 | $0.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $3.00 |
| AVG Volume (30 Days) | 6.3K | ★ 442.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.78 | ★ 35.14 |
| EPS | N/A | ★ N/A |
| Revenue | $1,336,000.00 | ★ $9,287,000.00 |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | 69.16 |
| 52 Week Low | $2.82 | $0.23 |
| 52 Week High | $7.13 | $1.05 |
Technical Indicators
Market Signals| Indicator | PLUR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 39.65 |
| Support Level | $3.13 | $0.27 |
| Resistance Level | $3.91 | $0.36 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 44.07 | 14.60 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.